The Online Investor
Biotechnology M&A image Biotechnology M&A » By The Online Investor Staff, updated Tue., Apr. 20, 2:20 AM Recent mergers and acquisitions in the Biotechnology M&A category.

Slide #62. BELLUS Health Inc. Thallion Pharmaceuticals Inc.

Acquirer: BELLUS Health Inc. (BLU.CA)
Acquiree: Thallion Pharmaceuticals Inc. (TLN.CA)
Details: BELLUS Health Inc. (TSX: BLU) ("BELLUS Health") and Thallion Pharmaceuticals Inc. ("Thallion") (TSXV: TLN) announced today that BELLUS Health has agreed to acquire Thallion for approximately $6.332 million in cash, or $0.1765 per share (on a fully-diluted basis), subject to certain adjustments as described below, and the issuance of contingent value rights ("CVRs"), which will entitle the holders thereof to additional payments of up to approximately $7.66 million, or $0.2135 per CVR, if certain product revenue milestones are achieved and a future receivable is collected.

BELLUS Health is a clinical-stage biopharmaceutical company. Co.'s primary drug candidate is BLU-5937, being developed for the treatment of chronic cough. In preclinical studies, BLU-5937 exhibited an anti-tussive effect without affecting taste perception and a safety profile. BLU-5937 has the potential to be therapeutic for chronic cough patients who do not respond to existing therapies. The Phase 1 data demonstrated that BLU-5937 has a tolerability profile, as well as a pharmacokinetic profile supporting twice-a-day dosing. Co. has obtained from NEOMED Institute an exclusive worldwide license to develop and commercialize BLU-5937.

Open the BLU.CA Page at The Online Investor »

BELLUS Health is a clinical-stage biopharmaceutical company. Co.'s primary drug candidate is BLU-5937, being developed for the treatment of chronic cough. In preclinical studies, BLU-5937 exhibited an anti-tussive effect without affecting taste perception and a safety profile. BLU-5937 has the potential to be therapeutic for chronic cough patients who do not respond to existing therapies. The Phase 1 data demonstrated that BLU-5937 has a tolerability profile, as well as a pharmacokinetic profile supporting twice-a-day dosing. Co. has obtained from NEOMED Institute an exclusive worldwide license to develop and commercialize BLU-5937.

Open the TLN.CA Page at The Online Investor »

Company Name: 
BELLUS Health Inc
Website: 
www.bellushealth.com
Sector: 
Biotechnology
Number of ETFs Holding BLU.CA: 
1
Total Market Value Held by ETFs: 
$183131
Total Market Capitalization: 
$238.00M
% of Market Cap. Held by ETFs: 
0.08%
Company Name: 
Thallion Pharmaceuticals Inc.
Website: 
www.thallion.com
Sector: 
Biotechnology
 

Quotes delayed 20 minutes


Biotechnology M&A - Slide 62 of 83 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2021, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.